(Q44557824)

English

Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats

scientific article published in November 2003

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

0 references

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Raymond T Bartus

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Dwaine F Emerich

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Joyce Hotz

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Marc Blaustein

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Reginald L Dean

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Brigido Perdomo

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Anthony S Basile

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

0 references

publication date

1 November 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Neuropsychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1973-1982

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Alteration of ethanol self-administration by naltrexone.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Retention and outcome in a narcotic antagonist treatment program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Chronic morphine and naltrexone fail to modify mu-opioid receptor mRNA levels in the rat brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Kinetics of a naltrexone sustained-release preparation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Pharmacological treatment of alcohol dependence: a review of the evidence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Endogenous opioid systems and alcohol addiction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

A month-long effect from a single injection of microencapsulated human growth hormone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

A method for fixation of previously fresh-frozen human adult and fetal brains that preserves histological quality and immunoreactivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Nontolerance to the opioid antagonism of naltrexone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Chronic naloxone results in prolonged increases in opiate binding sites in brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Advances in development of medications for alcoholism treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Naltrexone metabolism and sustained release following administration of an insoluble complex to rhesus monkeys and guinea-pigs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Naltrexone for alcohol dependence: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Simultaneous development of six LC-MS-MS methods for the determination of multiple analytes in human plasma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Six-month follow-up of naltrexone and psychotherapy for alcohol dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Reduction of alcohol drinking and upregulation of opioid receptors by oral naltrexone in AA rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Prolonged controlled-release of nafarelin, a luteinizing hormone-releasing hormone analogue, from biodegradable polymeric implants: influence of composition and molecular weight of polymer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Biodegradation and biocompatibility of PLA and PLGA microspheres

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Effects of naltrexone administered repeatedly across 30 or 60 days on ethanol consumption using a limited access procedure in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Quantitative immunolocalization of mu opioid receptors: regulation by naltrexone

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Naltrexone in the treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Chronic opioid antagonist treatment: assessment of receptor upregulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Naltrexone-induced opiate receptor supersensitivity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Naltrexone Maintenance: Effect on Morphine Sensitivity in Normal Volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

21 January 2018

Prevalence and correlates of alcohol use and DSM-IV alcohol dependence in the United States: results of the National Longitudinal Alcohol Epidemiologic Survey.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

7 January 2021

based on heuristic

inferred from DOI database lookup

Naltrexone in the treatment of alcohol dependence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

7 January 2021

based on heuristic

inferred from DOI database lookup

Naltrexone and coping skills therapy for alcohol dependence. A controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

7 January 2021

based on heuristic

inferred from DOI database lookup

Studies of EN-1639A (Naltrexone): A New Narcotic Antagonist

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic effects of leuprorelin microspheres on endometriosis and uterine leiomyomata

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

7 January 2021

based on heuristic

inferred from DOI database lookup

Naltrexone and alcohol dependence. Role of subject compliance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300274

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.NPP.1300274

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44557824&oldid=2206740228"